
SOTIO Biotech licenses ADCs from Lonza subsidiary Synaffix BV
Lonza's centre of excellence, Synaffix B.V. (Amsterdam, The Netherlands) has entered a licensing agreement with immuno-oncology specialist SOTIO...

BioLamina AB bags €19m funding for expansion
The tenth investement from Lauxera Capital Partners through its Lauxera Growth I fund will be usesd by the Swedish company to expand the development...

VectorY Therapeutics raises €129m in Series A round
EQT Life Sciences and Forbion co-led the €129m Series A financing that will support clinical development of VectorY Therapeutics BVs lead...

Memo Therapeutics AG raises CHF25m
The CHF25m Series C round of Schlieren-based Memo Therapeutics AG was led by Pureos Bioventures. Existing investors Swisscanto, Vesalius Biocapital,...

Abingworth raises $356m for new CCD fund
London-headquartered institutional investor Abingworth has closed its new Clinical Co-Development Co-Investment Fund at $356m, exceeding its target...

Mystery solved: Mysthera Theapeutics launches with $3.5m
Mysthera Therapeutics AG was just founded in Basel, Switzerland by Forty51 Ventures with $3.5m seed capital. Pursuing a first-in-class...

Researchers stop brain cell death in Alzheimer’s mice
The research team led by Prof. Bart De Strooper (VIB-KU Leuven/UK Dementia Research Institute), and Dr Sriram Balusu (VIB-KU Leuven) has finally...